Esperion’s experimental treatment for reducing cholesterol can impact millions of patients, according to CNBC, citing CEO Tim Mayleben. Esperion announced its treatment bempedoic acid reduced bad cholesterol, or LDL, by 18% in a clinical trial. The treatment was combined statins in the trial. Mayleben said the target is those who are taking a statin and not reaching their desired LDL goal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.